Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats: Implications for tardive dyskinesia?

Progress in Neurobiology

Volumn 61, Issue 5, 2000, Pages 525-541

  Andreassen, Ole A ^a   Jørgensen, Hugo A ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Basal ganglia; Excitotoxicity; Impaired Energy Metabolism; Motor side effects; Neurodegeneration; Neuroleptics; Oxidative stress; Rats; Tardive dyskinesia; Vacuous chewing movements

Indexed keywords

ALPHA TOCOPHEROL; CLOZAPINE; DIZOCILPINE; DOPAMINE 2 RECEPTOR; DYNORPHIN; FREE RADICAL; GANGLIOSIDE GM1; GLUTAMATE DECARBOXYLASE; GLUTAMIC ACID; HALOPERIDOL; HALOPERIDOL DECANOATE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; RISPERIDONE; SERTINDOLE; SUBSTANCE P;

ANIMAL EXPERIMENT; ANIMAL MODEL; BASAL GANGLION; CELL DEATH; ENERGY METABOLISM; MASTICATION; MORPHOLOGY; MOTOR ACTIVITY; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; REVIEW; TARDIVE DYSKINESIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; HUMANS; NEOSTRIATUM; NERVE DEGENERATION; NEUROTOXINS; OXIDATIVE STRESS; RATS;

EID: 0034256946     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(99)00064-7     Document Type: Review

References (179)

1. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:1989;366-375.
2. Andreassen O.A., Aamo T.O., Jørgensen H.A. Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats. Br. J. Pharmacol. 119:1996;751-757.
3. Andreassen O.A., Ferrante R.J., Beal M.F., Jørgensen H.A. Oral dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid. Neuroscience. 87:1998;639-648.
4. Andreassen O.A., Finsen B., Østergaard K., Sørensen J.C., West M.J., Jørgensen H.A. The relationship between oral dyskinesias produced by long-term haloperidol treatment, the density of striatal preproenkephalin messenger RNA and enkephalin peptide, and the number of striatal neurons expressing preproenkephalin messenger RNA in rats. Neuroscience. 88:1999;27-35.
5. Andreassen O.A., Jørgensen H.A. GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats. Psychopharmacology (Berl). 116:1994;517-522.
6. Andreassen O.A., Jørgensen H.A. The mitochondrial toxin 3-nitropropionic acid induces vacuous chewing movements in rats. Implications for tardive dyskinesia? Psychopharmacology (Berl). 119:1995;474-476.
7. Andreassen O.A., Jørgensen H.A. The rat model of tardive dyskinesia: relationship between vacuous chewing movements and gross motor activity during acute and long-term haloperidol treatment. Life Sci. 57:1995;2263-2272.
8. Andreassen O.A., MacEwan T., Gulbrandsen A.K., McCreadie R.G., Steen V.M. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology (Berl). 131:1997;174-179.
9. Andreassen O.A., Meshul C.K., Allen C., Jørgensen H.A. Oral dyskinesias and morphological changes in striatum in rats during long-term haloperidol treatment. Soc. Neurosci. Abstr. 23:1997;2415.
10. Andreassen, O.A., Fensen, B., Østergaard, K., West, M.J., Uørgensen, H.A., 2000. Reduced number of striatal neurons expressing preprosomatostatin mRNA in haloperidol treated rats with oral dyskinesia. Neurosci. Lett. (in press).
11. APA, 1992. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. APA Press, Washington DC.
12. Barak Y., Swartz M., Shamir E., Stein D., Weizman A. Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis. Ann. Clin. Psychiatry. 10:1998;101-105.
13. Barnes T.R., McPhillips M.A. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int. Clin. Psychopharmacol. 13:(Suppl 3):1998;S49-S57.
14. Bartzokis G., Garber H.J., Marder S.R., Olendorf W.H. MRI in tardive dyskinesia: shortened left caudate T2. Biol. Psychiatry. 28:1990;1027-1036.
15. Beal M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38:1995;357-366.
16. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13:1993;4181-4192.
17. Beal M.F., Hyman B.T., Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci. 16:1993;125-131.
18. Beasley C.M., Dellva M.A., Tamura R.N., Morgenstern H., Glazer W.M., Ferguson K., Tollefson G.D. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br. J. Psychiatry. 174:1999;23-30.
19. Behl C., Lezoulac'h F., Widmann M., Rupprecht R., Holsboer F. Oxidative stress-resistant cells are protected against haloperidol toxicity. Brain Res. 717:1996;193-195.
20. Behl C., Rupprecht R., Skutella T., Holsboer F. Haloperidol-induced cell death-mechanism and protection with vitamin E in vitro. Neuroreport. 7:1995;360-364.
21. Bloomquist J., King E., Wright A., Mytilineou C., Kimura K., Castagnoli K., Castagnoli N. Jr. 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies. J. Pharmacol. Exp. Ther. 270:1994;822-830.
22. Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. 166:1989;591-592.
23. Brouillet E., Jenkins B.G., Hyman B.T., Ferrante R.J., Kowall N.W., Srivastava R., Roy D.S., Rosen B.R., Beal M.F. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J. Neurochem. 60:1993;356-359.
24. Brown K., Reid A., White T., Henderson T., Hukin S., Johnstone C., Glen A. Vitamin E, lipids, and lipid peroxidation products in tardive dyskinesia. Biol. Psychiatry. 43:1998;863-867.
25. Burkhardt C., Kelly J.P., Lim Y.H., Filley C.M., Parker W.D. Jr. Neuroleptic medications inhibit complex I of the electron transport chain. Ann. Neurol. 33:1993;512-517.
26. Byczkowski J.Z., Borysewicz R. The action of chlorpromazine and imipramine on rat brain mitochondria. Gen. Pharmacol. 10:1979;369-372.
27. Cadet J.L., Kahler L.A. Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci. Biobehav. Rev. 18:1994;457-467.
28. Cadet J.L., Lohr J.B., Jeste D.V. Free radicals and tardive dyskinesia. Trends Neurosci. 9:1986;107-108.
29. Carlsson A. Does dopamine play a role in schizophrenia? Psychol. Med. 7:1977;583-597.
30. Casey D.E. Spontaneous and tardive dyskinesias: clinical and laboratory studies. J. Clin. Psychiatry. 46:1985;42-47.
31. Casey D.E. Tardive dyskinesia: reversible and irreversible. Psychopharmacology. 2:1985;88-97.
32. Casey D.E. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res. 35:1999;S61-S66.
33. Cavallero R., Smeraldi E. Antipsychotic-induced tardive dyskinesia: recognition, prevention and management. CNS Drugs. 4:1995;278-293.
34. Chakos M.H., Lieberman J.A., Bilder R.M., Borenstein M., Lerner G., Bogerts B., Wu H., Kinon B., Ashtari M. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am. J. Psychiatry. 151:1994;1430-1436.
35. Chen H.S., Pellegrini J.W., Aggarwal S.K., Lei S.Z., Warach S., Jensen F.E., Lipton S.A. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12:1992;4427-4436.
36. Clow A., Jenner P., Marsden C.D. Changes in dopamine-mediated behaviour during one year's neuroleptic administration. Eur. J. Pharmacol. 57:1979;365-375.
37. Coyle J.T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
38. Crane G.E. Persistent dyskinesia. Br. J. Psychiatry. 122:1973;395-405.
39. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 192:1976;481-483.
40. Dabiri L.M., Pasta D., Darby J.K., Mosbacher D. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am. J. Psychiatry. 151:1994;925-926.
41. Dawson R. Jr, Beal M.F., Bondy S.C., Di Monte D.A., Isom G.E. Excitotoxins, aging, and environmental neurotoxins: implications for understanding human neurodegenerative diseases. Toxicol. Appl. Pharmacol. 134:1995;1-17.
42. De Keyser K. Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia. Clin. Neuropharmacol. 14:1991;562-565.
43. Dickson P.R., Lang C.G., Hinton S.C., Kelley A.E. Oral stereotypy induced by amphetamine microinjection into striatum: an anatomical mapping study. Neuroscience. 61:1994;81-91.
44. Donzanti B.A., Hite J.F., Yamamoto B.K. Extracellular glutamate levels increase with age in the lateral striatum: potential involvement of presynaptic D-2 receptors. Synapse. 13:1993;376-382.
45. Egan M.F., Ferguson J., Hyde T.M. Effects of rating parameters on assessment of neuroleptic-induced vacuous chewing movements. Pharmacol. Biochem. Behav. 53:1996;401-410.
46. Egan M.F., Hurd Y., Ferguson J., Bachus S.E., Hamid E.H., Hyde T.M. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacology (Berl). 127:1996;337-345.
47. Egan M.F., Hurd Y., Hyde T.M., Weinberger D.R., Wyatt R.J., Kleinman J.E. Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias. Synapse. 18:1994;178-189.
48. Egan M.F., Hyde T.M., Albers G.W., Elkashef A., Alexander R.C., Reeve A., Blum A., Saenz R.E., Wyatt R.J. Treatment of tardive dyskinesia with vitamin E. Am. J. Psychiatry. 149:1992;773-777.
49. Egan M.F., Hyde T.M., Kleinman J.E., Wyatt R.J. Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose. Psychopharmacology (Berl). 117:1995;74-81.
50. Ellenbroek B.A. Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol. Ther. 57:1993;1-78.
51. Fang J., Zuo D., Yu P.H. Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells. Psychopharmacology (Berl). 121:1995;373-378.
52. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry. 49:1992;538-544.
53. Favaron M., Manev H., Alho H., Bertolino M., Ferret B., Guidotti A., Costa E. Gangliosides prevent glutamate and kainate neurotoxicity in primary neuronal cultures of neonatal rat cerebellum and cortex. Proc. Natl. Acad. Sci. USA. 85:1988;7351-7355.
54. Fibiger H.C., Lloyd K.G. Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends Neurosci. 7:1984;462-464.
55. 3H ]sulpiride binding in rat caudate-putamen: autoradiographic evidence for presynaptic D2 receptors on corticostriate terminals. Synapse. 2:1988;521-531.
56. Gallagher C.H., Koch J.H., Mann D.M. The effect of phenothiazone on the metabolism of liver mitochondria. Biochem. Pharmacol. 14:1965;799-811.
57. Gao X.M., Hashimoto T., Cooper T.B., Tamminga C.A. The dose-response characteristics of rat oral dyskinesias with chronic haloperidol or clozapine administration. J. Neural. Transm. 104:1997;97-104.
58. Gao X.M., Kakigi T., Friedman M.B., Tamminga C.A. Tiagabine inhibits haloperidol-induced oral dyskinesias in rats. J. Neural. Transm. Gen. Sect. 95:1994;63-69.
59. Gao X.M., Sakai K., Tamminga C.A. Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol. Neuropsychopharmacology. 19:1998;428-433.
60. Gardos G., Cole J.O. Severe tardive dyskinesia. Joseph A.B., Young R.R. Movement Disorders in Neurology and Neuropsychiatry. 1992;40-45 Blackwell, Cambridge.
61. Geinisman Y., Morrell F., deToledo-Morrell L. Remodeling of synaptic architecture during hippocampal "kindling" Proc. Natl. Acad. Sci. USA. 85:1988;3260-3264.
62. Glazer W.M., Morgenstern H., Schooler N., Berkman C.S., Moore D.C. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br. J. Psychiatry. 157:1990;585-592.
63. Glenthøj B. Persistent vacuous chewing in rats following neuroleptic treatment: relationship to dopaminergic and cholinergic function. Psychopharmacology. 113:1993;157-166.
64. Glenthøj B., Hemmingsen R. Intermittent neuroleptic treatment induces long-lasting abnormal mouthing in the rat. Eur. J. Pharmacol. 164:1989;393-396.
65. Glenthøj B., Hemmingsen R. Development of vacuous chewing movements in rats: role of housing environment. Life Sci. 48:1991;2137-2140.
66. Glenthøj B., Hemmingsen R., Allerup P., Bolwig T.G. Intermittent versus continuous neuroleptic treatment in a rat model. Eur. J. Pharmacol. 190:1990;275-286.
67. Goff D.C., Tsai G., Beal M.F., Coyle J.T. Tardive dyskinesia and substrates of energy metabolism in CSF. Am. J. Psychiatry. 152:1995;1730-1736.
68. Graybiel A.M. The basal ganglia. Trends Neurosci. 18:1995;60-62.
69. Graybiel A.M., Aosaki T., Flaherty A.W., Kimura M. The basal ganglia and adaptive motor control. Science. 265:1994;1826-1831.
70. Gunne L.M., Andersson U., Bondesson U., Johansson P. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol. Biochem. Behav. 25:1986;897-901.
71. Gunne L.M., Andren P.E. An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia. Clin. Neuropharmacol. 16:1993;90-95.
72. Gunne L.M., Growdon J., Glaeser B. Oral dyskinesia in rats following brain lesions and neuroleptic drug administration. Psychopharmacology. 77:1982;134-139.
73. Gunne L.M., Haggstrom J.E. Reduction of nigral glutamic acid decarboxylase in rats with neuroleptic-induced oral dyskinesia. Psychopharmacology. 81:1983;191-194.
74. Gunne L.M., Haggstrom J.E., Sjoquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature. 309:1984;347-349.
75. Guth P.S., Spirtes M.A. The phenothiazine tranquilizers: biochemical and biophysical actoins. Int. Rev. Neurobiol. 7:1964;231-278.
76. Gutierrez-Esteinou R., Grebb J.A. Risperidone: an analysis of the first three years in general use. Int. Clin. Psychopharmacol. 12:(4):1997;S3-S10.
77. Hamid E.H., Hyde T.M., Baca S.M., Egan M.F. Failure to down regulate NMDA receptors in the striatum and nucleus accumbens associated with neuroleptic-induced dyskinesia. Brain Res. 796:1998;291-295.
78. Han Z., Kuyatt B.L., Kochman K.A., DeSouza E.B., Roth G.S. Effect of aging on concentrations of D2-receptor-containing neurons in the rat striatum. Brain Res. 498:1989;299-307.
79. Hashimoto T., Ross D.E., Gao X.M., Medoff D.R., Tamminga C.A. Mixture in the distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia. Psychopharmacology (Berl). 137:1998;107-112.
80. Hyde T.M., Egan M.F., Wing L.L., Wyatt R.J., Weinberger D.R., Kleinman J.E. Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate. Psychopharmacology (Berl). 118:1995;142-149.
81. Iversen S.D., Howells R.B., Hughes R.P. Behavioral consequences of long-term treatment with neuroleptic drugs. Adv. Biochem. Psychopharmacol. 24:1980;305-313.
82. Jackson-Lewis V., Przedborski S., Kostic V., Suber F., Fahn S., Cadet J.L. Partial attenuation of chronic fluphenazine-induced changes in regional monoamine metabolism by D-alpha-tocopherol in rat brain. Brain. Res. Bull. 26:1991;251-258.
83. Jeding I., Evans P.J., Akanmu D., Dexter D., Spencer J.D., Aruoma O.I., Jenner P., Halliwell B. Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem. Pharmacol. 49:1995;359-365.
84. Jeste D.V., Lacro J.P., Bailey A., Rockwell E., Harris M.J., Caligiuri M.P. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J. Am. Geriatr. Soc. 47:1999;716-719.
85. Jeste D.V., Lohr J.B., Manley M. Study of neuropathologic changes in the striatum following 4, 8 and 12 months of treatment with fluphenazine in rats. Psychopharmacology. 106:1992;154-160.
86. Jeste D.V., Potkin S.G., Sinha S., Feder S., Wyatt R.J. Tardive dyskinesia-reversible and persistent. Arch. Gen. Psychiatry. 36:1979;585-590.
87. Johansson P., Casey D.E., Gunne L.M. Dose-dependent increase in rat spontaneous chewing rates during long-term administration of haloperidol but not clozapine. Psychopharmacol. Bull. 22:1986;1017-1019.
88. Johansson P.E., Terenius L., Haggstrom J.E., Gunne L. Neuropeptide changes in a primate model (Cebus apella) for tardive dyskinesia. Neuroscience. 37:1990;563-567.
89. Jørgensen H.A., Andreassen O.A., Hole K. The relationship between motor effects in rats following acute and chronic haloperidol treatment. Psychopharmacology (Berl). 116:1994;89-92.
90. Kakigi T., Gao X.M., Tamminga C.A. Drug-induced oral dyskinesias in rats after traditional and new neuroleptics. J. Neural. Transm. Gen. Sect. 101:1995;41-49.
91. Kane J.M. Tardive dyskinesia. Joseph A.B., Young R.R. Movement Disorders in Neurology and Neuropsychiatry. 1992;33-39 Blackwell, Cambridge.
92. Kane J.M. Tardive dyskinesia: epidemiology and clinical presentation. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. vol. 39:1995;1485-1495 Raven Press, New York.
93. Kane J.M., Smith J.M. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch. Gen. Psychiatry. 39:1982;473-481.
94. Kane J.M., Weinhold P., Kinon B., Wegner J., Leader M. Prevalence of abnormal involuntary movements ("spontaneous dyskinesias") in the normal elderly. Psychopharmacology. 77:1982;105-108.
95. Kaneda H., Shirakawa O., Dale J., Goodman L., Bachus S.E., Tamminga C.A. Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats. Eur. J. Pharmacol. 212:1992;43-49.
96. Kelley A.E., Bakshi V.P., Delfs J.M., Lang C.G. Cholinergic stimulation of the ventrolateral striatum elicits mouth movements in rats: pharmacological and regional specificity. Psychopharmacology. 99:1989;542-549.
97. Kelley J.J., Gao X.M., Tamminga C.A., Roberts R.C. The effect of chronic haloperidol treatment on dendritic spines in the rat striatum. Exp. Neurol. 146:1997;471-478.
98. Kharlamov A., Guidotti A., Costa E., Hayes R., Armstrong D. Semisynthetic sphingolipids prevent protein kinase C translocation and neuronal damage in the perifocal area following a photochemically induced thrombotic brain cortical lesion. J. Neurosci. 13:1993;2483-2494.
99. Knable M.B., Hyde T.M., Egan M.F., Tosayali M., Wyatt R.J., Kleinman J.E. Quantitative autoradiography of striatal dopamine D1, D2 and re-uptake sites in rats with vacuous chewing movements. Brain Res. 646:1994;217-222.
100. Koller W., Curtin J., Fields J. Molindone compared to haloperidol in a guinea-pig model of tardive dyskinesia. Neuropharmacology. 23:1984;1191-1194.
101. Levinson A.J., Garside S., Rosebush P.I., Mazurek M.F. Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the rat. Neuroscience. 84:1998;201-211.
102. Levy A.D., See R.E., Levin E.D., Ellison G.D. Neuroleptic-induced oral movements in rats: methodological issues. Life Sci. 41:1987;1499-1506.
103. Lezoualc'h F., Rupprecht R., Holsboer F., Behl C. Bcl-2 prevents hippocampal cell death induced by the neuroleptic drug haloperidol. Brain Res. 738:1996;176-179.
104. Liminga U., Gunne L.M. Intranigral stimulation of oral movements by [Pro9] substance P, a neurokinin-1 receptor agonist, is enhanced in chronically neuroleptic-treated rats. Behav. Brain Res. 57:1993;93-99.
105. Lipton S.A. Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci. 16:1993;527-532.
106. Lohr J.B. Oxygen radicals and neuropsychiatric illness. Some speculations. Arch. Gen. Psychiatry. 48:1991;1097-1106.
107. Lohr J.B., Kuczenski R., Bracha H.S., Moir M., Jeste D.V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol. Psychiatry. 28:1990;535-539.
108. Manev H., Costa E., Wroblewski J.T., Guidotti A. Abusive stimulation of excitatory amino acid receptors: a strategy to limit neurotoxicity. Faseb J. 4:1990;2789-2797.
109. Manev H., Favaron M., Vicini S., Guidotti A., Costa E. Glutamate-induced neuronal death in primary cultures of cerebellar granule cells: protection by synthetic derivatives of endogenous sphingolipids. J. Pharmacol. Exp. Ther. 252:1990;419-427.
110. Maura G., Carbone R., Raiteri M. Aspartate-releasing nerve terminals in rat striatum possess D-2 dopamine receptors mediating inhibition of release. J. Pharmacol. Exp. Ther. 251:1989;1142-1146.
111. Maurer I., Moller H.J. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol. Cell Biochem. 174:1997;255-259.
112. McGeer E.G., McGeer P.L. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature. 263:1976;517-519.
113. Meshul C.K., Andreassen O.A., Allen C., Jørgensen H.A. Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol. Psychopharmacology (Berl). 125:1996;238-247.
114. Meshul C.K., Janowsky A., Casey D.E., Stallbaumer R.K., Taylor B. Effect of haloperidol and clozapine on the density of "perforated" synapses in caudate, nucleus accumbens, and medial prefrontal cortex. Psychopharmacology. 106:1992;45-52.
115. Meshul C.K., Stallbaumer R.K., Taylor B., Janowsky A. Haloperidol-induced morphological changes in striatum are associated with glutamate synapses. Brain Res. 648:1994;181-195.
116. Miller R., Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol. Psychiatry. 34:1993;713-738.
117. Mion C.C., Andreasen N.C., Arndt S., Swayze V.W.D., Cohen G.A. MRI abnormalities in tardive dyskinesia. Psychiatry Res. 40:1991;157-166.
118. Mistry R., Wilke R., Challiss R.A. Modulation of NMDA effects on agonist-stimulated phosphoinositide turnover by memantine in neonatal rat cerebral cortex. Br. J. Pharmacol. 114:1995;797-804.
119. 3H ]-glutamic acid release by dopaminergic drugs. Life Sci. 26:1980;2073-2081.
120. Mithani S., Atmadja S., Baimbridge K.G., Fibiger H.C. Neuroleptic-induced oral dyskinesias: effects of progabide and lack of correlation with regional changes in glutamic acid decarboxylase and choline acetyltransferase activities. Psychopharmacology. 93:1987;94-100.
121. Miwa Y., Koshikawa N., Miyata N., Koshida Y., Kobayashi M., Cools A.R. YM-14673, a thyrotropin-releasing hormone analogue, injected into the nucleus accumbens and the striatum produces repetitive jaw movements in rats. Eur. J. Pharmacol. 277:1995;63-69.
122. Moghaddam B., Bunney B.S. Depolarization inactivation of dopamine neurons: terminal release characteristics. Synapse. 14:1993;195-200.
123. Morgenstern H., Glazer W.M. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia study. Arch. Gen. Psychiatry. 50:1993;723-733.
124. Morselli P.L., Fournier V., Bossi L., Musch B. Clinical activity of GABA agonists in neuroleptic- and L-dopa-induced dyskinesia. Psychopharmacology. 2:1985;128-136.
125. Nagy J.I., Carter D.A., Fibiger H.C. Anterior striatal projections to the globus pallidus entopeduncular nucleus and substantia nigra in the rat: the GABA connection. Brain Res. 158:1978;15-29.
126. Nielsen E.B., Lyon M. Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (flupenithixol) in rats. Psychopharmacology (Berl). 59:1978;85-89.
127. Nobile-Orazio E., Carpo M., Scarlato G. Gangliosides: their role in clinical neurology. Drugs. 47:1994;576-585.
128. Novelli A., Reilly J.A., Lysko P.G., Henneberry R.C. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. 451:1988;205-212.
129. Pakkenberg H., Fog R., Nilakantan B. The long-term effect of perphenazine enanthate on the rat brain. Some metabolic and anatomical observations. Psychopharmacologia. 29:1973;329-336.
130. Palacios J.M., Camps M., Cortés R., Charuchinda C. Characterization and distribution of brain dopamine receptors. Jankovic J., Tolosa E. Parkinson's Disease and Movement Disorders. 1988;27-36 Urban and Schwartzenberg, Baltimore-Munich.
131. Pall H.S., Williams A.C., Blake D.R., Lunec J. Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet. 2:1987;596-599.
132. Parsons C.G., Gruner R., Rozental J., Millar J., Lodge D. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology. 32:1993;1337-1350.
133. Pepeu, G., Oderfeld-Nowak, B., Casamenti, F., 1993. CNS pharmacology of gangliosides. In: Svennerholm, P., Ashburg, A.K., Reisfeld, R.A., Sandhoff, K., Suzuki, K., Tettarrianti, G., Toffano, G. (Eds.), Progress in Brain Research. Elsevier. 101, 327-335.
134. Petersen R., Andreassen O.A., Zimmer J., Jørgensen H.A., Finsen B. Dopamine D1 receptor mRNA modulation in the rat dorsal striatum after chronic haloperidol treatment: implications for neuroleptic-induced oral dyskinesia. Soc. Neurosci. Abstr. 23:1997;1932.
135. Post A., Holsboer F., Behl C. Induction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-kappaB and neuroprotection by antioxidants. J. Neurosci. 18:1998;8236-8246.
136. Price M.T., Olney J.W., Haft R. Age-related changes in glutamate concentration and synaptosomal glutamate uptake in adult rat striatum. Life Sci. 28:1981;1365-1370.
137. Prince J.A., Yassin M.S., Oreland L. Neuroleptic-induced mitochondrial enzyme alterations in the rat brain. J. Pharmacol. Exp. Ther. 280:1997;261-267.
138. Roberts R.C., Gaither L.A., Gao X.M., Kashyap S.M., Tamminga C.A. Ultrastructural correlates of haloperidol-induced oral dyskinesias in rat striatum. Synapse. 20:1995;234-243.
139. Rogawski M.A. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. 14:1993;325-331.
140. Rollema H., Skolnik M., D'Engelbronner J., Igarashi K., Usuki E., Castagnoli N. Jr. MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J. Pharmacol. Exp. Ther. 268:1994;380-387.
141. Røsengarten H., Schweitzer J.W., Friedhoff A.J. Possible genetic factors underlying the pathophysiology of tardive dyskinesia. Pharmacol. Biochem. Behav. 49:1994;663-667.
142. Rupniak N.M., Jenner P., Marsden C.D. Cholinergic manipulation of perioral behaviour induced by chronic neuroleptic administration to rats. Psychopharmacology. 79:1983;226-230.
143. Rupniak N.M., Jenner P., Marsden C.D. Pharmacological characterisation of spontaneous or drug-associated purposeless chewing movements in rats. Psychopharmacology. 85:1985;71-79.
144. Rupniak N.M., Jenner P., Marsden C.D. Acute dystonia induced by neuroleptic drugs. Psychopharmacology. 88:1986;403-419.
145. Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J. Neurochem. 71:1998;1002-1012.
146. Schwarcz R., Creese I., Coyle J.T., Snyder S.H. Dopamine receptors localised on cerebral cortical afferents to rat corpus striatum. Nature. 271:1978;766-768.
147. See R.E. Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride. Neurosci. Lett. 129:1991;265-268.
148. See R.E., Chapman M.A. Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats. Eur. J. Pharmacol. 263:1994;269-276.
149. See R.E., Ellison G. Intermittent and continuous haloperidol regimens produce different types of oral dyskinesias in rats. Psychopharmacology. 100:1990;404-412.
150. See R.E., Lynch A.M. Chronic haloperidol potentiates stimulated glutamate release in caudate putamen, but not prefrontal cortex. Neuroreport. 6:1995;1795-1798.
151. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719.
152. Seeman P., Van Tol H.H. Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15:1994;264-270.
153. Shigenaga M.K., Hagen T.M., Ames B.N. Oxidative damage and mitochondrial decay in aging. Proc. Natl. Acad. Sci. USA. 91:1994;10771-10778.
154. Shirakawa O., Tamminga C.A. Basal ganglia GABAA and dopamine D1 binding site correlates of haloperidol-induced oral dyskinesias in rat. Exp. Neurol. 127:1994;62-69.
155. Steen V.M., Lovlie R., MacEwan T., McCreadie R.G. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol. Psychiatry. 2:1997;139-145.
156. Tamminga C.A., Crayton J.W., Chase T.N. Improvement in tardive dyskinesia after muscimol therapy. Arch. Gen. Psychiatry. 36:1979;595-598.
157. Tamminga C.A., Dale J.M., Goodman L., Kaneda H., Kaneda N. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology. 102:1990;474-478.
158. Tamminga C.A., Gerlach J. New neuroleptics and experimental antipsychotics in schizophrenia. Meltzer H.Y. Psychopharmacology: The Third Generation of Progress. 1987;1129-1140 Raven Press, New York.
159. Tamminga C.A., Thaker G.K., Ferraro T.N., Hare T.A. GABA agonist treatment improves tardive dyskinesia. Lancet. 2:1983;97-98.
160. Tamminga C.A., Thaker G.K., Nguyen J.A. GABAmimetic treatments for tardive dyskinesia: efficacy and mechanism. Psychopharmacol. Bull. 25:1989;43-46.
161. Tsai G., Goff D.C., Chang R.W., Flood J., Baer L., Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am. J. Psychiatry. 155:1998;1207-1213.
162. Turski L., Ikonomidou C. Toward an understanding of tardive dyskinesia: chronic haloperidol enhances NMDA toxicity in mouse striatum. Soc. Neurosci. Abstr. 21:1995;1744.
163. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Jr. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44:1985;559-577.
164. Waddington J.L. Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, its neurobiological determinants, and the conflict of paradigms. Int. Rev. Neurobiol. 31:1989;297-353.
165. Waddington J.L. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology. 101:1990;431-447.
166. Waddington J.L., Cross A.J., Gamble S.J., Bourne R.C. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science. 220:1983;530-532.
167. Waddington J.L., Youssef H.A. An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms. Am. J. Psychiatry. 143:1986;1162-1165.
168. Wallace D.C. Mitochondrial diseases in man and mouse. Science. 283:1999;1482-1488.
169. Weinhold P., Wegner J.T., Kane J.M. Familial occurrence of tardive dyskinesia. J. Clin. Psychiatry. 42:1981;165-166.
170. Weiss B., Santelli S. Dyskinesias evoked in monkeys by weekly administration of haloperidol. Science. 200:1978;799-801.
171. Woerner M.G., Alvir J.M., Saltz B.L., Lieberman J.A., Kane J.M. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am. J. Psychiatry. 155:1998;1521-1528.
172. Woerner M.G., Kane J.M., Lieberman J.A., Alvir J., Bergmann K.J., Borenstein M., Schooler N.R., Mukherjee S., Rotrosen J., Rubinstein M., et al. The prevalence of tardive dyskinesia. J. Clin. Psychopharmacol. 11:1991;34-42.
173. Wolfarth S., Ossowska K. Can the supersensitivity of rodents to dopamine be regarded as a model of tardive dyskinesia? Prog. Neuropsychopharmacol. Biol. Psychiatry. 13:1989;799-840.
174. Yamamoto B.K., Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 14:1994;4159-4166.
175. Yamamoto B.K., Davy S. Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J. Neurochem. 58:1992;1736-1742.
176. Yassa R., Ananth J. Familial tardive dyskinesia. Am. J. Psychiatry. 138:1981;1618-1619.
177. Yassa R., Jeste D.V. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr. Bull. 18:1992;701-715.
178. Yokoyama H., Kasai N., Ueda Y., Niwa R., Konaka R., Mori N., Tsuchihashi N., Matsue T., Ohya-Nishiguchi H., Kamada H. In vivo analysis of hydrogen peroxide and lipid radicals in the striatum of rats under long-term administration of a neuroleptic. Free Radic. Biol. Med. 24:1998;1056-1060.
179. Zachowski A., Durand P. Biphasic nature of the binding of cationic amphipaths with artificial and biological membranes. Biochim. Biophys. Acta. 937:1988;411-416.